<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clonidine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clonidine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clonidine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11609" href="/d/html/11609.html" rel="external">see "Clonidine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13171" href="/d/html/13171.html" rel="external">see "Clonidine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708678"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Epidural use: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The 500 mcg/mL strength product should be diluted prior to use in an appropriate solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Note: Epidural clonidine is not recommended for obstetrical, postpartum, or perioperative pain management. The risk of hemodynamic instability, especially hypotension and bradycardia, from epidural clonidine may be unacceptable in these patients. However, in a rare obstetrical, postpartum or perioperative patient, potential benefits may outweigh the possible risks.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F153485"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Catapres [DSC];</li>
<li>Catapres-TTS-1;</li>
<li>Catapres-TTS-2;</li>
<li>Catapres-TTS-3;</li>
<li>Duraclon;</li>
<li>Kapvay [DSC];</li>
<li>Nexiclon XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866397"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Clonidine;</li>
<li>MAR-Clonidine;</li>
<li>MINT-CloNIDine;</li>
<li>MINT-Clonidine;</li>
<li>Sandoz Clonidine;</li>
<li>TEVA-CloNIDine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F153534"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha<sub>2</sub>-Adrenergic Agonist;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F153489"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Do <b>not</b> discontinue therapy abruptly. Taper gradually to avoid withdrawal symptoms (eg, rebound hypertension).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Oral doses are expressed as clonidine hydrochloride and transdermal patch doses are expressed as clonidine base. Oral doses cannot be converted directly to a transdermal patch due to bioavailability differences.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>IR tablets and ER formulations are <b>not</b> interchangeable due to different pharmacokinetic profiles.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>). For severe asymptomatic hypertension, may consider short-term oral use for BP lowering (eg, over hours) if there is concern that severe BP elevation will precipitate an acute cardiovascular event, such as in patients with known aortic or intracranial aneurysms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Varon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Varon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 0.1 mg twice daily; increase dose in increments of 0.1 mg/day at weekly intervals based on response and tolerability; patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication adjustment within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354','lexi-content-ref-Mann.1'])">Ref</a></span>); usual dose range: 0.2 to 0.6 mg/day in 2 divided doses. The manufacturer's labeling includes a maximum daily dose of 2.4 mg; however, doses &gt;0.6 mg/day are generally not used.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (Nexiclon): Initial: 0.17 mg once daily at bedtime; increase dose in increments of 0.09 mg/day at weekly intervals based on response and tolerability; usual dose range: 0.17 to 0.52 mg once daily; maximum dose: 0.52 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Initial: 0.1 mg per 24-hour patch applied once every 7 days; increase by 0.1 mg at 1- to 2-week intervals; usual dose range: 0.1 to 0.3 mg per 24-hour patch applied once every 7 days. Onset of effect is delayed for 2 to 3 days following initial application.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients undergoing surgery, maintenance dose is generally continued perioperatively to avoid rebound hypertension associated with abrupt withdrawal. ER tablets (Nexiclon) may be administered up to 28 hours prior to surgery and resumed the following day. It may be appropriate to transition to a transdermal patch ≥3 days before surgery in select patients who are not expected to resume enteral medication ≤12 hours after surgery. See "Transitioning Between Dosage Forms" below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Muluk.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Muluk.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a5c0d61-3369-40a6-b2b7-8bea78288a0a">ICU sedation, transition from dexmedetomidine to clonidine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>ICU sedation, transition from dexmedetomidine to clonidine (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider use in patients who are hemodynamically stable and able to receive medications enterally. Monitor blood pressure and heart rate during initiation and transition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25809176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25809176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial: Note:</b> Decrease dexmedetomidine dose by 25% within 6 hours of each clonidine dose. Dexmedetomidine can usually be stopped within 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dexmedetomidine dose &lt;0.7 mcg/kg/hour</i>: 0.1 to 0.2 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25809176','lexi-content-ref-28833346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25809176','lexi-content-ref-28833346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dexmedetomidine dose ≥0.7 mcg/kg/hour:</i> 0.3 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25809176','lexi-content-ref-28833346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25809176','lexi-content-ref-28833346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance:</b> Titrate to achieve target sedation levels to a usual dosage range of 0.2 to 0.5 mg every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25809176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25809176'])">Ref</a></span>). Gradually taper clonidine by extending the dosing interval every 24 to 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25809176','lexi-content-ref-28833346','lexi-content-ref-27092265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25809176','lexi-content-ref-28833346','lexi-content-ref-27092265'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8bd222bf-1d89-40a0-9f96-e15e03c7c8c0">Opioid withdrawal, medically supervised</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid withdrawal, medically supervised (adjunctive or alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adjunct to opioid agonist for relief of withdrawal symptoms. May also be used as primary treatment when opioid agonist therapy is not indicated or not available. May be combined with other adjunctive medications as needed. To assess severity of withdrawal symptoms and adjust therapy, the use of a standard instrument for scoring of clinical observations (eg, Clinical Opioid Withdrawal Scale) is suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleber.1','lexi-content-ref-32511106','lexi-content-ref-Stolbach.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleber.1','lexi-content-ref-32511106','lexi-content-ref-Stolbach.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initial:</b> 0.1 to 0.2 mg (patients &gt;90 kg may receive up to 0.3 mg); may repeat every 45 to 60 minutes if needed, up to a total of 4 doses until symptoms resolve, provided blood pressure and heart rate remain stable; maximum dose: typically, 0.8 mg/day or up to 1.2 mg/day for patients &gt;90 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleber.1','lexi-content-ref-Sevarino.1','lexi-content-ref-Stolbach.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleber.1','lexi-content-ref-Sevarino.1','lexi-content-ref-Stolbach.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance:</b> 0.1 to 0.3 mg every 6 to 8 hours determined by symptom severity; maximum dose: 1.2 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> After a stable oral dose is established, may transition to an equivalent dose of a transdermal patch (see "Transitioning between dosage forms" below); according to some institutional protocols, may initiate therapy with a transdermal patch in select patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kleber.1','lexi-content-ref-27140827','lexi-content-ref-Sevarino.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kleber.1','lexi-content-ref-27140827','lexi-content-ref-Sevarino.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider use when menopausal hormonal therapy is contraindicated and when other nonhormonal therapies are ineffective or not tolerated. Side effects (eg, dry mouth, dizziness, constipation, hypotension, sedation) may limit use. Transdermal administration may provide more stable serum concentrations to help limit side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26444994','lexi-content-ref-26872610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26444994','lexi-content-ref-26872610'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>
<b>:</b> Immediate release: 0.05 mg twice daily; discontinue treatment if no improvement after 2 to 4 weeks (Canadian manufacturer's labeling). Some experts recommend upward titration based on response and tolerability to a dosage range of 0.1 to 1 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Santen.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Santen.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal (off label):</b> Initial: 0.1 mg/24-hour patch applied once every 7 days; increase to 0.2 mg/24-hour patch then 0.3 mg/24-hour patch based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Santen.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Santen.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between dosage forms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transition from IR tablets to ER (Nexiclon) tablets:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">0.05 mg twice daily of immediate release is equivalent to 0.09 mg once daily of extended release (Nexiclon).</p>
<p style="text-indent:-2em;margin-left:6em;">0.1 mg twice daily of immediate release is equivalent to 0.17 mg once daily of extended release (Nexiclon).</p>
<p style="text-indent:-2em;margin-left:6em;">0.2 mg twice daily of immediate release is equivalent to 0.34 mg once daily of extended release (Nexiclon).</p>
<p style="text-indent:-2em;margin-left:6em;">0.3 mg twice daily of immediate release is equivalent to 0.52 mg once daily of extended release (Nexiclon).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transition from oral to transdermal:</i></b>
<b>Note:</b> If transitioning from oral to transdermal therapy, overlap oral regimen for 1 to 3 days; transdermal route takes 2 to 3 days to achieve therapeutic effect.</p>
<p style="text-indent:-2em;margin-left:6em;">An example transition is below:</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1: Place transdermal patch; administer 100% of oral dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 2: Patch remains; administer 50% of oral dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3: Patch remains; administer 25% of oral dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Day 4: Patch remains; no further oral dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transition from transdermal to oral:</i></b> After transdermal patch removal, therapeutic clonidine levels persist for ~8 hours and then slowly decrease over several days, with a potential for continued effect for 24 to 48 hours after removal. A persistent effect on blood pressure should be considered when restarting oral clonidine. Consider starting oral clonidine no sooner than 8 hours after patch removal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Muluk.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Muluk.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b> Do not stop oral therapy abruptly to decrease risk of rebound hypertension and other withdrawal symptoms (eg, nervousness, agitation, headache, tremor); discontinue slowly over 6 to 10 days by reducing the dose by one-third to one-half every 2 to 3 days. For patients on both a beta-blocker and clonidine, withdraw the beta-blocker several days before clonidine, then slowly taper clonidine. Rebound hypertension and withdrawal symptoms are less likely with a transdermal patch compared to oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Elliott.2019','lexi-content-ref-6115570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Elliott.2019','lexi-content-ref-6115570'])">Ref</a></span>). <b>Note:</b> Clonidine administration is generally not interrupted during the perioperative period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Muluk.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Muluk.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990659"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">Clonidine is excreted primarily through the kidneys as unchanged drug (40% to 60%). For this reason, dose initiation and titration should be done cautiously with monitoring of response in patients with significant kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>). Additionally, patients with advanced kidney impairment may have impaired alpha-adrenergic responsiveness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3293868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3293868'])">Ref</a></span>); individualize dose according to patient response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, transdermal:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Start with a low dose and titrate upward cautiously according to patient response, no more frequently than for patients with normal kidney function; monitor BP and heart rate closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Minimally dialyzable (0% to 5%):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ER tablet (Kapvay), IR tablet, transdermal:</b> Start with a low dose and titrate upward cautiously according to patient response, no more frequently than for patients with normal kidney function; monitor BP and heart rate closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>); no supplemental dose postdialysis is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ER tablet (Nexiclon): </b>Initiate at 0.09 mg once daily at bedtime; titrate upward cautiously.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzable (highly lipid soluble) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, transdermal: </b>Start with a low dose and titrate upward cautiously according to patient response, no more frequently than for patients with normal kidney function; monitor BP and heart rate closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: Initial:</b> Start with a low dose and titrate upward cautiously according to patient response, no more frequently than for patients with normal kidney function; monitor BP and heart rate closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: Initial:</b> Start with a low dose and titrate upward cautiously according to patient response, no more frequently than for patients with normal kidney function; monitor BP and heart rate closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987877"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F153490"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension: </b>
<b>Note:</b> Avoid as first-line treatment due to risk of CNS effects, bradycardia, and orthostatic hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Consider initiating at a lower dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 0.1 mg once daily at bedtime, increase gradually as needed.</p></div>
<div class="block dop drugH1Div" id="F153510"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13171" href="/d/html/13171.html" rel="external">see "Clonidine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> To avoid adverse effects (eg, rebound hypertension), do <b>not</b> discontinue clonidine abruptly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing is expressed as the salt (clonidine hydrochloride) unless otherwise noted. Extemporaneously compounded oral suspensions are available in multiple concentrations (eg, 0.01 mg/mL, 0.02 mg/mL, 0.1 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as <b>mcg</b> or mg as appropriate (ie, not in mL or number of tablets).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Immediate-release (tablets) vs extended-release (Kapvay [tablets], Nexiclon XR [tablets]) formulations of clonidine are not interchangeable on a mg per mg basis due to different pharmacokinetic profiles. Extended-released formulations (Kapvay [tablets] vs Nexiclon XR [tablets]) are not interchangeable on a mg:mg basis; only Kapvay is approved for use in pediatric patients. Transdermal patch is a membrane-controlled system; do <b>not</b> cut the patch to deliver partial doses; if cut, rate of drug delivery, reservoir contents, and adhesion may be affected; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9262751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9262751'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD) (alternative or adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or as an adjunct to stimulant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31570648','lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31570648','lexi-content-ref-17581453'])">Ref</a></span>). May be optimal for patients with comorbid tics or Tourette syndrome, a history of psychosis or mania, or emotional dysregulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥6 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581453','lexi-content-ref-3523578','lexi-content-ref-Hunt.1','lexi-content-ref-8496122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581453','lexi-content-ref-3523578','lexi-content-ref-Hunt.1','lexi-content-ref-8496122'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">Weight 27 to 40.5 kg: Oral: Initial: 0.05 mg at bedtime; sequentially increase as tolerated every 2 to 3 days in 0.05 mg/day increments given as 0.05 mg twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.2 mg/<b>day</b>. <b>Note: </b>Dosing interval of twice daily or 3 times daily preferred by some experts for ease of dosing and increased compliance. When discontinuing therapy, taper over 1 to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">Weight &gt;40.5 to 45 kg: Oral: Initial: 0.05 mg at bedtime; sequentially increase as tolerated every 2 to 3 days in 0.05 mg/day increments given as 0.05 mg twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.3 mg/<b>day</b>. <b>Note: </b>Dosing interval of twice daily or 3 times daily preferred by some experts for ease of dosing and increased compliance. When discontinuing therapy, taper over 1 to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:10em;">Weight &gt;45 kg: Oral: Initial: 0.1 mg at bedtime; sequentially increase as tolerated every 2 to 3 days in 0.1 mg/day increments given as 0.1 mg twice daily, then 3 times daily, then 4 times daily; maximum daily dose: 0.4 mg/<b>day</b>. <b>Note:</b> Dosing interval of twice daily or 3 times daily preferred by some experts for ease of dosing and increased compliance. When discontinuing therapy, taper over 1 to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended-release tablets</i> (eg, Kapvay or associated generics): Children ≥6 years and Adolescents: Oral: Initial: 0.1 mg at bedtime; increase as tolerated in 0.1 mg/day increments every 7 days until desired response; after initial dose, doses should be administered twice daily in the morning and at bedtime (either split equally or with the higher split dosage given at bedtime); maximum daily dose: 0.4 mg/<b>day</b>. <b>Note:</b> When discontinuing therapy, taper daily dose by ≤0.1 mg every 3 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b> Transdermal patch: Limited data available: Children ≥6 years and Adolescents: May be converted to the transdermal delivery system after oral therapy is titrated to an optimal and stable dose; a transdermal dose approximately equivalent to the total oral daily dose may be used; apply transdermal patch and change every 5 to 7 days. Adjustment of transdermal patch dose may be needed; there is variation in absorption and no exact equivalence or fixed ratio exist between the oral and transdermal routes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18696285','lexi-content-ref-3523578','lexi-content-ref-Hunt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18696285','lexi-content-ref-3523578','lexi-content-ref-Hunt.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89391235-7434-4a8c-a182-de1eb8897f00">Growth hormone deficiency test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth hormone deficiency test: </b>Limited data available: Children and Adolescents: Oral: Immediate release: 5 <b>mcg</b>/kg or 150 <b>mcg/m<sup>2</sup></b> as a single dose; maximum dose: 250 <b>mcg</b>/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7040621','lexi-content-ref-18425584','lexi-content-ref-31865218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7040621','lexi-content-ref-18425584','lexi-content-ref-31865218'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent</b>
<b>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute severe hypertension with significant but not life-threatening symptoms (eg, severe headache, vomiting but no seizures):</i> Limited data available: Children and Adolescents: Oral: Immediate release: 2 to 5 <b>mcg</b>/kg/dose; may repeat dose every 6 to 8 hours; maximum dose: 10 <b>mcg</b>/kg/dose up to a maximum total dose of 0.8 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-18839219','lexi-content-ref-15286277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-18839219','lexi-content-ref-15286277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic hypertension:</i>
<b>Note: </b>Clonidine is no longer recommended for primary use in children with chronic hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-15286277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-15286277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88f974a8-6223-4053-89f3-428f246a8626">Insomnia, especially with neurodevelopmental disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, especially with neurodevelopmental disorders (alternative therapy)</b>: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Most commonly used in patients with comorbid ADHD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33223070','lexi-content-ref-16740821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33223070','lexi-content-ref-16740821'])">Ref</a></span>). The use of clonidine for insomnia in patients without neurodevelopmental disorders is based on expert clinical experience (limited/no published data); use should be reserved for patients who have failed nonpharmacologic interventions and in whom other underlying contributors have been identified and appropriately managed. When discontinuing, gradually reduce dose over 2 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-9884677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-9884677'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;27 kg: Oral: Initial: 25 to 50 <b>mcg</b> at bedtime; titrate in 25 <b>mcg</b> increments every 1 to 2 weeks as tolerated; usual daily dose: 5 to 10 <b>mcg</b>/kg/<b>day</b>; maximum daily dose: 10 <b>mcg</b>/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight 27 to 40.5 kg: Oral: Initial: 25 to 50 <b>mcg</b> at bedtime; titrate in 25 <b>mcg</b> increments every 1 to 2 weeks as tolerated; maximum daily dose: 0.2 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842','lexi-content-ref-9884677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842','lexi-content-ref-9884677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;40.5 kg to 45 kg: Oral: Initial: 25 to 50 <b>mcg</b> at bedtime; titrate in 25 <b>mcg</b> increments every 1 to 2 weeks as tolerated; maximum daily dose: 0.3 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842','lexi-content-ref-9884677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842','lexi-content-ref-9884677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &gt;45 kg: Oral: Initial: 25 to 50 <b>mcg</b> at bedtime; titrate in 25 <b>mcg</b> increments every 1 to 2 weeks as tolerated; maximum daily dose: 0.4 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-28921528','lexi-content-ref-31638842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (PTSD):</b> Very limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 5 to ≤10 years: Oral: Immediate release: Initial: 0.05 mg at bedtime; may titrate in 0.05 mg increments every 3 days; reported target dose: 0.2 to 0.5 mg/<b>day</b>; the total daily dose should be divided into multiple doses per day due to the short half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12725011','lexi-content-ref-20441729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12725011','lexi-content-ref-20441729'])">Ref</a></span>); 3-times-daily dosing has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12656438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12656438'])">Ref</a></span>); maximum daily dose: 0.5 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20441729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20441729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;10 years and Adolescents: Oral: Immediate release: Initial: 0.1 mg at bedtime; may titrate in 0.05 to 0.1 mg increments every 3 days based on tolerability and response; <b>Note: </b>Dose titration based on available literature and clinical expertise adapted from use for other clinical diagnoses (eg, attention-deficit/hyperactivity disorder); reported target dose: 0.2 to 0.5 mg/<b>day</b>; the total daily dose should be divided into multiple doses per day due to the short half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12725011','lexi-content-ref-20441729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12725011','lexi-content-ref-20441729'])">Ref</a></span>); 3-times-daily dosing has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12656438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12656438'])">Ref</a></span>); maximum daily dose: 0.5 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20441729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20441729'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tic disorder:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Efficacy results variable; compared to placebo, clonidine may be more likely to reduce tic severity, with largest effects observed in patients with comorbid ADHD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208','lexi-content-ref-29219631','lexi-content-ref-23099282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208','lexi-content-ref-29219631','lexi-content-ref-23099282'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Oral: Immediate release: Initial: 0.025 to 0.05 mg/<b>day </b>in 1 to 2 divided doses; gradual titration to a 3- to 4-times-daily schedule using small increments (0.025 mg); usual daily dose: 0.1 to 0.4 mg/<b>day</b> in 3 to 4 divided doses; reported maximum daily dose: 0.6 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24290467','lexi-content-ref-11886028','lexi-content-ref-19433274','lexi-content-ref-2009034','lexi-content-ref-22397999','lexi-content-ref-11865128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24290467','lexi-content-ref-11886028','lexi-content-ref-19433274','lexi-content-ref-2009034','lexi-content-ref-22397999','lexi-content-ref-11865128'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090165"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: Oral: Extended release (eg, Kapvay): The manufacturer recommends dosage adjustment according to degree of renal impairment; however, there are no specific dosage adjustment provided in the labeling (has not been studied). Bradycardia, sedation, and hypotension may be more likely to occur in patients with renal failure; drug is primarily eliminated unchanged in the urine; consider using doses at the lower end of the dosage range; monitor patients closely.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable (0 to 5%); supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51090166"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55209984"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradycardia and hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia</b> and <b>hypotension</b> may occur with therapeutic or supratherapeutic dosing of clonidine in all ages. These adverse reactions may require intervention, and they are generally reversible with discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (consistently with bradycardia; more variable with hypotension); related to the pharmacologic action (ie, central alpha-2 adrenergic receptor agonist-mediated reduction in sympathetic outflow) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23757186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23757186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during therapy. Varies based on dosage form (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21984028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21984028'])">Ref</a></span>). May occur within 30 minutes of oral administration (most significant effects within 1 to 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5568234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5568234'])">Ref</a></span>). There is a 2- to 3-day delay in onset for transdermal administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16227779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16227779'])">Ref</a></span>). Most hypotensive episodes occur within the first 4 days with epidural administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9649979','lexi-content-ref-9363412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9649979','lexi-content-ref-9363412'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Hypotension:</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent antihypertensives or antipsychotics</p>
<p style="text-indent:-2em;margin-left:8em;">• History of bradycardia, dehydration, hypotension, or syncope</p>
<p style="text-indent:-2em;margin-left:8em;">• Perioperative use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24679061','lexi-content-ref-21984028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24679061','lexi-content-ref-21984028'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Transdermal preparations in the setting of a degraded skin barrier and excessive dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33005940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33005940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Epidural administration</p>
<p style="text-indent:-2em;margin-left:10em;">- Concurrent narcotic analgesics</p>
<p style="text-indent:-2em;margin-left:10em;">- Females</p>
<p style="text-indent:-2em;margin-left:10em;">- Hemodynamic instability</p>
<p style="text-indent:-2em;margin-left:10em;">- Low body weight</p>
<p style="text-indent:-2em;margin-left:10em;">- Severe cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:10em;">- Use in obstetrical or postpartum patients</p>
<p style="text-indent:-2em;margin-left:6em;">Bradycardia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cardiac conduction abnormalities</p>
<p style="text-indent:-2em;margin-left:8em;">• Clinical sinus node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3341873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3341873'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of medications that impact sinus node function or AV node conduction (eg, beta-blockers, digoxin, diltiazem, verapamil)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of bradycardia, or dehydration, hypotension, or syncope</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3341873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3341873'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients who develop bradycardia while taking other sympatholytic medications or who are concurrently taking another sympatholytic medication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3341873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3341873'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Perioperative use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24679061','lexi-content-ref-21984028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24679061','lexi-content-ref-21984028'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Transdermal preparations in the setting of a degraded skin barrier and excessive dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33005940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33005940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Epidural administration</p>
<p style="text-indent:-2em;margin-left:10em;">- Use in obstetrical or postpartum patients</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome/rebound hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A <b>withdrawal syndrome</b>, primarily characterized by a rapid increase in blood pressure (rebound hypertension), may occur upon abrupt discontinuation of clonidine, regardless of administration route. Additional symptoms may include <b>diaphoresis,</b> flushing, <b>headache</b>, and <b>insomnia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15857353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15857353'])">Ref</a></span>). Risk may be lower with transdermal clonidine administration due to a more gradual reduction in drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896146'])">Ref</a></span>). Blood pressure may exceed pretreatment levels in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15857353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15857353'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; result of excessive plasma catecholamine levels, “catecholamine surge” (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15857353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15857353'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically occurs within 4 to 24 hours of drug discontinuation but may occur up to 72 hours after drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15857353','lexi-content-ref-26370679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15857353','lexi-content-ref-26370679'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent cardioselective beta-blocker therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use (&gt;1 to 2 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15857353']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15857353'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (&gt;1 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-760743','lexi-content-ref-3026180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-760743','lexi-content-ref-3026180'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension</p>
<p style="text-indent:-2em;margin-left:6em;">• Medication nonadherence</p>
<p style="text-indent:-2em;margin-left:6em;">• Vomiting (abrupt inability to absorb oral dosage forms)</p>
<p style="text-indent:-2em;margin-left:6em;">• Empty infusion pump drug reservoir (neuraxial administration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infusion pump malfunction (neuraxial administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8659804','lexi-content-ref-26370679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8659804','lexi-content-ref-26370679'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F153448"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral, Transdermal:</b> Incidence of adverse reactions may be less with transdermal compared to oral due to the lower peak/trough ratio.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (transdermal: 8% to 34%), transient skin rash (localized; characterized by pruritus and erythema; transdermal: 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Upper abdominal pain (15%), xerostomia (0% to 40%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia-oral-transdermal')">table 1</a>)</span><span class="table-link" style="display:none;">Xerostomia (Oral, Transdermal)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia (Oral, Transdermal)" frame="border" id="lexi-content-xerostomia-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Xerostomia (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-dizziness-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness-oral-transdermal')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness (Oral, Transdermal)</span>, drowsiness (12% to 38%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-oral-transdermal')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness (Oral, Transdermal)</span>, fatigue (6% to 16%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-fatigue-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue-oral-transdermal')">table 4</a>)</span><span class="table-link" style="display:none;">Fatigue (Oral, Transdermal)</span>, headache (5% to 20%)<span class="lexi-table-link-container"> (<a aria-label="Headache (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-headache-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache-oral-transdermal')">table 5</a>)</span><span class="table-link" style="display:none;">Headache (Oral, Transdermal)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness (Oral, Transdermal)" frame="border" id="lexi-content-dizziness-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Dizziness (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness (Oral, Transdermal)" frame="border" id="lexi-content-drowsiness-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Drowsiness (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue (Oral, Transdermal)" frame="border" id="lexi-content-fatigue-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Fatigue (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache (Oral, Transdermal)" frame="border" id="lexi-content-headache-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Headache (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg//day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (4%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia-oral-transdermal')">table 6</a>)</span><span class="table-link" style="display:none;">Bradycardia (Oral, Transdermal)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia (Oral, Transdermal)" frame="border" id="lexi-content-bradycardia-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Bradycardia (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (transdermal: 3%), contact hypersensitivity (transdermal: 5%), excoriation of skin (transdermal: 3%), hyperpigmentation (transdermal: 5%), macular eruption (transdermal: 1%), papule of skin (transdermal: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1% to 10%), dysgeusia (transdermal: 1%), nausea (1% to 5%), viral gastrointestinal infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (transdermal: ≤2%), sexual disorder (transdermal: ≤2%), urinary incontinence (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized blanching (transdermal: 1%), localized edema (transdermal: 3%), localized vesiculation (transdermal: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (1% to 3%), emotional disturbance (4%), insomnia (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Insomnia (Oral, Transdermal) table link" class="lexi-table-link" data-table-id="lexi-content-insomnia-oral-transdermal" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-insomnia-oral-transdermal')">table 7</a>)</span><span class="table-link" style="display:none;">Insomnia (Oral, Transdermal)</span>, irritability (5% to 9%), lethargy (3%), nervousness (1%), night terrors (3%), nightmares (4% to 9%), restless sleep (3%), sedated state (3% to 10%), sleep disorder (1% to 3%), throbbing (transdermal: 1%), tremor (1% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Insomnia (Oral, Transdermal)" frame="border" id="lexi-content-insomnia-oral-transdermal" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Insomnia (Oral, Transdermal)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">78</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.2 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablet</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder (ADHD)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">76</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Transdermal patch</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (3%; acute)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry throat (transdermal: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Crying (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block, chest pain, heart failure, orthostatic hypotension, palpitations, prolonged QT interval on ECG, Raynaud disease, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic<b>: </b>Alopecia, hypopigmentation (localized), pallor, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia, increased serum glucose (transient), loss of libido, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, gastrointestinal pseudo-obstruction, parotitis, salivary gland pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy, difficulty in micturition, erectile dysfunction, nocturia, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive direct Coombs’ test, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (mild; transient), hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, asthenia, behavioral changes, cerebrovascular accident, decreased sexual activity, delirium, delusion, depression, hallucination (visual and auditory), malaise, numbness (localized), paresthesia, restlessness, vivid dream, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase in blood specimen (transient), lower limb cramp, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blurred vision, burning sensation of eyes, decreased lacrimation, dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Epidural:</b> The following adverse reactions occurred more often than placebo in cancer patients with intractable pain being treated with concurrent epidural morphine.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (45%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension (Epidural) table link" class="lexi-table-link" data-table-id="lexi-content-hypotension-epidural" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension-epidural')">table 8</a>)</span><span class="table-link" style="display:none;">Hypotension (Epidural)</span>, orthostatic hypotension (32%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic hypotension (Epidural) table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension-epidural" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension-epidural')">table 9</a>)</span><span class="table-link" style="display:none;">Orthostatic hypotension (Epidural)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension (Epidural)" frame="border" id="lexi-content-hypotension-epidural" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Hypotension (Epidural)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">45%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mcg/hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Epidural infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Analgesia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic hypotension (Epidural)" frame="border" id="lexi-content-orthostatic-hypotension-epidural" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Orthostatic hypotension (Epidural)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mcg/hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Epidural infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Analgesia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (13%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia (Epidural) table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia-epidural" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia-epidural')">table 10</a>)</span><span class="table-link" style="display:none;">Xerostomia (Epidural)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia (Epidural)" frame="border" id="lexi-content-xerostomia-epidural" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Xerostomia (Epidural)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mcg/hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Epidural infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Analgesia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (13%), dizziness (13%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness (Epidural) table link" class="lexi-table-link" data-table-id="lexi-content-dizziness-epidural" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness-epidural')">table 11</a>)</span><span class="table-link" style="display:none;">Dizziness (Epidural)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness (Epidural)" frame="border" id="lexi-content-dizziness-epidural" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Dizziness (Epidural)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mcg/hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Epidural infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Analgesia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (5%)<span class="lexi-table-link-container"> (<a aria-label="Diaphoresis (Epidural) table link" class="lexi-table-link" data-table-id="lexi-content-diaphoresis-epidural" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diaphoresis-epidural')">table 12</a>)</span><span class="table-link" style="display:none;">Diaphoresis (Epidural)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diaphoresis (Epidural)" frame="border" id="lexi-content-diaphoresis-epidural" rules="all">
<caption style="text-align:center;">
<b>Clonidine: Adverse Reaction: Diaphoresis (Epidural)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clonidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mcg/hour</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Epidural infusion</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Analgesia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">38</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">47</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hallucination (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (5%)</p></div>
<div class="block coi drugH1Div" id="F153463"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to clonidine hydrochloride or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Epidural administration: Injection site infection; concurrent anticoagulant therapy; bleeding diathesis; administration above the C4 dermatome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe bradyarrhythmia from second- or third-degree atrioventricular block or sick sinus syndrome; sinus node dysfunction; hereditary problems of galactose intolerance (eg, galactosemia).</p></div>
<div class="block war drugH1Div" id="F153445"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression (including sedation and somnolence), which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, including recent MI. Epidural clonidine is not recommended for use in patients with severe cardiovascular disease or hemodynamic instability.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with chronic renal impairment. The hemodynamic effects may be prolonged in those with renal impairment; elimination half-life significantly prolonged (up to 41 hours) in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural use<b>:</b> Should be administered via continuous epidural infusion device.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Oral formulations of clonidine (immediate release versus extended release) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles. Oral extended-release formulations of clonidine (Kapvay [indicated for attention-deficit/hyperactivity disorder in pediatric patients] vs Nexiclon XR [indicated for hypertension in adults]) are not interchangeable on a mg:mg basis due to different pharmacokinetic profiles.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. Due to the potential for altered electrical conductivity, remove transdermal patch before cardioversion or defibrillation. Localized contact sensitization to the transdermal system has been reported; in these patients, allergic reactions (eg, generalized rash, urticaria, angioedema) have also occurred following subsequent substitution of oral therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Clonidine may cause eye dryness in patients who wear contact lenses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Gradual withdrawal is needed (discontinue oral immediate release or epidural dose gradually over 6 to 10 days to avoid rebound hypertension) if drug needs to be stopped. Patients should be instructed about abrupt discontinuation (causes rapid increase in BP and symptoms of sympathetic overactivity). In patients on both a beta-blocker and clonidine where withdrawal of clonidine is necessary, withdraw the beta-blocker first and several days before clonidine withdrawal, then slowly decrease clonidine.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878393"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Prior to treatment with medications for attention-deficit/hyperactivity disorder (ADHD), the American Heart Association and the American Academy of Pediatrics recommend that all children and adolescents diagnosed with ADHD have a thorough cardiovascular assessment, including patient and family health histories, determination of all medications used (prescribed and over-the-counter), and a physical examination focused on cardiovascular disease risk factors. An ECG is not mandatory but is reasonable to consider prior to stimulant medication therapy. Prompt evaluation and appropriate referral and testing, if warranted, should occur if any cardiac symptoms present (Vetter 2008). These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). ECG abnormalities and 4 cases of sudden cardiac death have been reported in children receiving clonidine with methylphenidate; a dose reduction of methylphenidate when used concurrently with clonidine has been suggested; consider ECG monitoring. In patients with ADHD, clonidine may cause hypotension and bradycardia; use with caution in patients with history of hypotension, heart block, bradycardia, cardiovascular disease, syncope, conditions predisposing to syncope (including orthostatic hypotension, dehydration), or receiving concomitant antihypertensive therapy. Patients should be advised to avoid becoming dehydrated or overheated. Heart rate and blood pressure should be monitored at initiation of therapy, with any dose increase, and periodically during therapy.</p></div>
<div class="block foc drugH1Div" id="F153455"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Catapres-TTS-1: 0.1 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Catapres-TTS-2: 0.2 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Catapres-TTS-3: 0.3 mg/24 hr (4 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg/24 hr (1 ea, 4 ea); 0.2 mg/24 hr (1 ea, 4 ea); 0.3 mg/24 hr (1 ea, 4 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Epidural, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duraclon: 100 mcg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/mL (10 mL); 500 mcg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Catapres: 0.1 mg [DSC] [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Catapres: 0.2 mg [DSC], 0.3 mg [DSC] [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg, 0.2 mg, 0.3 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kapvay: 0.1 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexiclon XR: 0.17 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.17 mg</p></div>
<div class="block geq drugH1Div" id="F153441"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F153466"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Catapres-TTS-1 Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $87.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Catapres-TTS-2 Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/24 hrs (per each): $146.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Catapres-TTS-3 Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/24 hrs (per each): $203.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (cloNIDine Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/24 hrs (per each): $33.12 - $78.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg/24 hrs (per each): $55.77 - $131.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/24 hrs (per each): $77.36 - $182.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (cloNIDine HCl (Analgesia) Epidural)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/mL (per mL): $3.13 - $5.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg/mL (per mL): $12.25 - $19.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Duraclon Epidural)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/mL (per mL): $5.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (cloNIDine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg (per each): $4.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (cloNIDine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.17 mg (per each): $19.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Nexiclon XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.17 mg (per each): $21.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (cloNIDine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg (per each): $0.05 - $0.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.2 mg (per each): $0.08 - $0.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per each): $0.13 - $0.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866398"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg, 0.2 mg</p></div>
<div class="block adm drugH1Div" id="F153460"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural:</b> Specialized techniques are required for continuous epidural administration; administration via this route should only be performed by qualified individuals familiar with the techniques of epidural administration and patient management problems associated with this route. Familiarization of the epidural infusion device is essential. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2 to 3 days to avoid withdrawal symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be taken with or without food. Swallow whole with water (0.025 mg tablet [Canadian product]). Swallow ER tablets (Kapvay) whole; do not crush, chew, or split. ER tablets (Nexiclon) are scored tablets and may be split in half. Administer ER tablets (Nexiclon) preferably at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transdermal patch:</b> Patches should be applied weekly at a consistent time to a clean, hairless area of the upper outer arm or chest. Rotate patch sites weekly. Redness under patch may be reduced if a topical corticosteroid spray is applied to the area before placement of the patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7949510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7949510'])">Ref</a></span>). Dispose of any used or unused patches by folding adhesive ends together, replace in pouch or sealed container, and discard properly in trash away from children and pets.</p></div>
<div class="block admp drugH1Div" id="F52612442"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals. Do not discontinue clonidine abruptly.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release (Kapvay): Swallow whole; do not crush, chew, or split.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Patches should be applied at bedtime to a clean, hairless area of the upper arm or chest. In adults, patches are applied every 7 days, rotating patch sites weekly; in children, the patch may need to be changed more frequently (eg, every 5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10835999','lexi-content-ref-3602304','lexi-content-ref-Hunt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10835999','lexi-content-ref-3602304','lexi-content-ref-Hunt.1'])">Ref</a></span>); in adults, redness under patch may be reduced if a topical corticosteroid spray is applied to the area before placement of the patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7949510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7949510'])">Ref</a></span>); <b>Note:</b> Transdermal patch is a membrane-controlled system; do <b>not</b> cut the patch to deliver partial doses; rate of drug delivery, reservoir contents, and adhesion may be affected if cut; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9262751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9262751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Epidural: Not for IV use. Visually inspect for particulate matter and discoloration prior to administration (whenever permitted by container and solution). Specialized techniques are required for continuous epidural administration; administration via this route should only be performed by qualified individuals familiar with the techniques of epidural administration and patient management problems associated with this route. Familiarization of the epidural infusion device is essential. Do not discontinue clonidine abruptly; if needed, gradually reduce dose over 2 to 4 days to avoid withdrawal symptoms.</p></div>
<div class="block use drugH1Div" id="F153459"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ER tablet [Kapvay]):</b> Treatment of attention-deficit/hyperactivity disorder (monotherapy or as adjunctive therapy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (ER tablet [Nexiclon], IR tablet, and transdermal patch):</b> Management of hypertension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (0.</b>
<b>025 mg tablet [</b>
<b>Canadian product]): </b>Relief of menopausal flushing in patients for whom hormonal replacement therapy is unnecessary or not desirable.</p></div>
<div class="block off-label drugH1Div" id="F25722040"><span class="drugH1">Use: Off-Label: Adult</span><p>ICU sedation, transition from dexmedetomidine to clonidine; Opioid withdrawal, medically supervised; Vasomotor symptoms associated with menopause</p></div>
<div class="block mst drugH1Div" id="F153543"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CloNIDine may be confused with Clomid, clomiPHENE, clonazePAM, cloZAPine, KlonoPIN, quiNIDine</p>
<p style="text-indent:-2em;margin-left:4em;">Catapres may be confused with Cataflam, Combipres</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Clonidine is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older for hypertension treatment due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha agonists. Avoid clonidine as a first-line antihypertensive (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Use caution when interpreting dosing information. Pediatric dose for epidural infusion expressed as mcg/kg/<b>hour</b>.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI. Errors have occurred when the inactive, optional adhesive cover has been applied instead of the active clonidine-containing patch.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299067"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F153450"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of CloNIDine. Alcohol (Ethyl) may increase the serum concentration of CloNIDine. Specifically, the rate of dissolution from the clonidine extended-release tablet may be enhanced in the presence of alcohol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): CloNIDine may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CloNIDine may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58234677"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Consider transitioning from clonidine to an agent preferred for use during pregnancy in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019); clonidine is considered an alternative option due to possible side effects (SOGC [Magee 2022]).</p></div>
<div class="block pri drugH1Div" id="F153467"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clonidine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Clonidine concentrations in the umbilical cord plasma are similar to those in the maternal serum and concentrations in the amniotic fluid may be 4 times those in the maternal serum.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of clonidine may be altered during pregnancy due to an increase in nonrenal clearance, possibly regulated by maternal CYP2D6 genotype (Buchanan 2009; Claessens 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension is initiated during pregnancy, agents other than clonidine may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). Clonidine is considered an alternative option due to possible side effects (SOGC [Magee 2022]); use should be considered in consult with subspecialists (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on outcome data following use for hypertension during pregnancy, clonidine may be used in pregnant patients with attention-deficit/hyperactivity disorder (ADHD) when needed (Ornoy 2021). Data collection to monitor pregnancy and infant outcomes following exposure to ADHD medications is ongoing. Health care providers are encouraged to enroll patients exposed to Kapvay during pregnancy in the National Pregnancy Registry for ADHD Medications (866-961-2388).</p>
<p style="text-indent:0em;margin-top:2em;">Clonidine has been evaluated for use as an adjunctive agent for epidural labor analgesia (Allen 2018; Cavens 2022; Kumari 2018; Xia 2022; Zhang 2015), including patients who are opioid dependent (Hoyt 2018); however, the manufacturer does not recommend epidural clonidine for obstetrical or postpartum pain due to the risk of hemodynamic instability. Severe maternal hypotension may occur following epidural use, which may result in decreased placental perfusion. Potential benefits may outweigh the possible risks in some obstetrical or postpartum patients.</p>
<p style="text-indent:0em;margin-top:2em;">Clonidine has been evaluated for the management of opioid withdrawal; however, withdrawal management using clonidine is not preferred for patients who are pregnant (ASAM 2020).</p></div>
<div class="block brc drugH1Div" id="F153468"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Clonidine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of clonidine in breast milk are available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk samples were obtained on the first 3 days postpartum from 3 women administered oral clonidine 0.3 mg/day. Treatment was initiated 1 to 23 days prior to delivery. Clonidine concentrations were 0.8 to 2.8 ng/mL in breast milk and 0.4 to 1.5 ng/mL in the maternal plasma (Boutroy 1988).</p>
<p style="text-indent:-2em;margin-left:4em;">• Data are available from a lactating patient, 4 weeks postpartum, taking oral clonidine 0.0.375 mg twice daily. Clonidine concentrations were 0.33 ng/mL in the maternal plasma (1 hour after the dose), 0.6 ng/mL in breast milk (2.5 hours after the dose), and undetectable (&lt;0.096 ng/mL) in the infant plasma, 1 hour after breastfeeding (Bunjes 1993).</p>
<p style="text-indent:-2em;margin-left:4em;">• Clonidine concentrations in breast milk were approximately twice those of the maternal serum in 9 patients treated with clonidine during pregnancy and postpartum. Breast milk and maternal serum were sampled 1 to 5 days, 10 to 14 days, and 45 to 60 days after delivery. Clonidine was also measurable in the breastfed infant serum at each time point (Hartikainen-Sorri 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">• Based on available lactation studies, one manufacturer reports the relative infant dose of clonidine to be 4.1% to 8.4% of the weight adjusted maternal dose (maternal dose and milk concentrations not presented).</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events observed in some breastfed infants also exposed in utero include apathy syndrome, hypoglycemia, hypotonia, drowsiness, feeding difficulties, and hyperexcitability (Hartikainen-Sorri 1987; Sevrez 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. When treatment for hypertension is needed in a breastfeeding patient, clonidine may be acceptable for use (ESC [Cífková 2020]); however, due to adverse events observed in breastfeeding infants, other sources do not recommend use in patients who are breastfeeding (Ornoy 2021) or recommend avoiding use when breastfeeding infants born &lt;34 weeks' gestation or when large maternal doses are needed (Atkinson 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Infants exposed to clonidine via breast milk should be monitored for symptoms of hypotension and/or bradycardia (eg, sedation, lethargy, tachypnea, poor feeding).</p></div>
<div class="block mop drugH1Div" id="F153453"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP, heart rate, mental status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural:</b> Carefully monitor infusion pump; inspect catheter tubing for obstruction or dislodgement to reduce risk of inadvertent abrupt withdrawal of infusion. Monitor closely for catheter-related infection (eg, meningitis or epidural abscess).</p></div>
<div class="block pha drugH1Div" id="F153444"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates alpha-2 adrenoceptors in the brain stem, thus activating an inhibitory neuron, resulting in reduced sympathetic outflow from the CNS, producing a decrease in peripheral resistance, renal vascular resistance, heart rate, and blood pressure; epidural clonidine may produce pain relief at spinal presynaptic and postjunctional alpha-2 adrenoceptors by preventing pain signal transmission; pain relief occurs only for the body regions innervated by the spinal segments where analgesic concentrations of clonidine exist. For the treatment of ADHD, the mechanism of action is unknown; it has been proposed that postsynaptic alpha-2 agonist stimulation regulates subcortical activity in the prefrontal cortex, the area of the brain responsible for emotions, attentions, and behaviors and causes reduced hyperactivity, impulsiveness, and distractibility. Epidurally administered clonidine produces dose-dependent analgesia not antagonized by opiate antagonists. The analgesia is limited to the body regions innervated by the spinal segments where analgesic concentrations of clonidine are present. Clonidine is thought to produce analgesia at presynaptic and postjunctional alpha-2 adrenoceptors in the spinal cord by preventing pain signal transmission to the brain.</p></div>
<div class="block phk drugH1Div" id="F153462"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Antihypertensive effect: Oral: Immediate release: 0.5 to 1 hour (maximum reduction in blood pressure: 2 to 4 hours); Transdermal: Initial application: 2 to 3 days; Transdermal: Steady state reached in ~3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Attention-deficit/hyperactivity disorder: Oral: Extended release (Kapvay): Onset of action: 1 to 2 weeks (AAP [Wolraich 2011]).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Extended-release tablets (Kapvay) are not bioequivalent with immediate-release formulations; peak plasma concentrations are 50% lower compared to immediate-release formulations.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~2.9 L/kg; highly lipid soluble; distributes readily into extravascular sites.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Epidurally administered clonidine readily distributes into plasma via the epidural veins and attains clinically significant systemic concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 20% to 40%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic to inactive metabolites; undergoes enterohepatic recirculation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Immediate release: 70% to 80%; Extended release (Kapvay): ~89% (relative to immediate-release formulation); Transdermal: ~60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 6.13 ± 1.33 hours (Lonnqvist 1993).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Normal renal function: 12 to 16 hours; Renal impairment: ≤41 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Epidural administration: CSF half-life elimination: 1.3 ± 0.5 hours; plasma half-life elimination: 22 ± 15 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Transdermal: Half-life elimination (after patch removal): ~20 hours (due to skin depot effect; increase in plasma clonidine concentrations may occur after patch removal [MacGregor 1985]).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: Immediate release: 1 to 3 hours; Extended release (Kapvay): 7 to 8 hours; Extended release (Nexiclon): 7.8 ± 1.7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (40% to 60% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance:</p>
<p style="text-indent:-4em;margin-left:8em;">Oral:</p>
<p style="text-indent:-4em;margin-left:10em;">Neonates: 0.16 L/kg/hour (Xie 2011).</p>
<p style="text-indent:-4em;margin-left:10em;">Infants and Children ≤4 years: ~0.3 L/kg/hour (Xie 2011).</p>
<p style="text-indent:-4em;margin-left:10em;">Children 5 to 10 years: ~0.26 L/kg/hour (Xie 2011).</p>
<p style="text-indent:-4em;margin-left:10em;">Adults: Single dose: ~0.25 L/kg/hour; Multiple dose: ~0.4 L/kg/hour (Frisk-Holmberg 1981).</p></div>
<div class="block phksp drugH1Div" id="F51220851"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life increases up to 41 hours in patients with severe renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038585"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arkamin | Catapres</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidina gray</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-clonidine | Catapres | Catapres clonidine hydrochloride | Clonidine | Clonidine scp</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonipres</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Catapressan | Dixarit</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Chlophazolin | Clonidon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Atensina | Clonesina | Neo clodil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Clonidine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidin | Clonidina | Clonidina E-cardio | Clonidina winthrop</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Haemiton</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidin | Clonidin ratiopharm | Clonistada | Haemiton | Paracefan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cataperten | Catapresan | Clonidina mamey | Cloniperten | Coasin | Iclotan | Karpatil | Presonal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Chlophazolin | Clophelin | Haemiton</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Catapres</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Caprysin | Catapresan | Clonisin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Catapressan | Clonidine Dci | Clonidine rpg</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Catapres tts | Clonidine | Clonidine sandoz | Clonidine teva | Dixarit</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Catapresan | Catapressan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-clonidine | Catapres | Dixarit</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Clonidin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonidine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonidine | Dixarit</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Clonnirit | Normopresan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Arkamin | Arkapres | Catapres | Clodict | Clonithem | Clopresyn | Nefropres c | Nefropress c</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adesipress | Catapresan | Clonidina provvisoria</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Catapres</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonidine | Kapvay | Senidine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Catapressan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo clonidin | Catapresan | Chlophazolin | Clophelin | Haemiton | Iporel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Catapressan | Dixarit</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Chlophazolin | Clophelin | Haemiton</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Catapressan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bomath | Catapresan | Clonidina | Epiclodina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Clonidine bnm | Dixarit</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidine HCL | Clonidine Hcl Actavis | Clonidine hcl PCH | Clonidine hcl sandoz | Dixarit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carexarit | Catapresan | Catapresan glenwood | Catapresan tts-2 | Catapresan unimedic | Catapress TTS | Catapressan | Clonidin ratiopharm | Clonidine | Clonidine hcl aurobindo | Clonidine hcl cf | Iporel | Kapvay | Teva Clonidine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonidine | Clonidine teva | Dixarit</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alphapres | Catamed | Catapin | Catapres | Clodin | Clonidine | Clonigen | Clonimed | Clonipress</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Haemiton | Iporel | Paracefan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonidine | Clonidine HCL | Clonidine hcl er | Clonidine hydrochloride er | Kapvay | Nexiclon xr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Clonistada</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clonidina | Clonidine | Haemiton</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Clofelin | Clophelin | Haemiton</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Catapres</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dixarit</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Catapress | Catapressan | Clonidin ratiopharm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Catapresan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Capril | Catapres | Coropress | Hypodine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Catapressan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Catapres</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Catapren | Catapres | Chianda | Clodin | Clonidine | Dixarit | Hypolax | Kochaniin | Pinsanidine | Winpress</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clophelin | Clophelinum | Clophelinum ic | Haemiton</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Epyclon | Normopresin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Catapresan | Clonidina | Clonipres | Naclodin | Velaril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Catapres | Dixarit | Menograine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398463">
<a name="19398463"></a>Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an Adjunct Therapy to Opioids for Neonatal Abstinence Syndrome: A Randomized, Controlled Trial. <i>Pediatrics</i>. 2009;123(5):e849-e856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19398463/pubmed" id="19398463" target="_blank">19398463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29406172">
<a name="29406172"></a>Allen TK, Mishriky BM, Klinger RY, Habib AS. The impact of neuraxial clonidine on postoperative analgesia and perioperative adverse effects in women having elective Caesarean section-a systematic review and meta-analysis. <i>Br J Anaesth</i>. 2018;120(2):228-240. doi:10.1016/j.bja.2017.11.085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/29406172/pubmed" id="29406172" target="_blank">29406172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511106">
<a name="32511106"></a>American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. <i>J Addict Med</i>. 2020;14(2S)(suppl 1):1‐91. doi:10.1097/ADM.0000000000000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/32511106/pubmed" id="32511106" target="_blank">32511106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1728876">
<a name="1728876"></a>Atkin SH, Jaker MA, Beaty P, et al. Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. <i>Am J Med Sci.</i> 1992;303(1):9-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/1728876/pubmed" id="1728876" target="_blank">1728876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3292101">
<a name="3292101"></a>Atkinson HC, Begg EJ, Darlow BA. Drugs in Human Milk. Clinical Pharmacokinetic Considerations. <i>Clin Pharmacokinet</i>. 1988;14(4):217-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3292101/pubmed" id="3292101" target="_blank">3292101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26872610">
<a name="26872610"></a>Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. <i>Climacteric</i>. 2016;19(2):109-150. doi:10.3109/13697137.2015.1129166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26872610/pubmed" id="26872610" target="_blank">26872610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25624389">
<a name="25624389"></a>Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. <i>Pediatrics</i>. 2015;135(2):e383-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25624389/pubmed" id="25624389" target="_blank">25624389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164354">
<a name="34164354"></a>Bader MY, Zaghloul N, Repholz A, et al. A retrospective review following the addition of clonidine to a neonatal abstinence syndrome treatment algorithm. <i>Front Pediatr</i>. 2021;9:632836. doi:10.3389/fped.2021.632836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/34164354/pubmed" id="34164354" target="_blank">34164354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26799351">
<a name="26799351"></a>Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. <i>Pharmacotherapy</i>. 2016;36(1):84-98. doi:10.1002/phar.1686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26799351/pubmed" id="26799351" target="_blank">26799351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3208682">
<a name="3208682"></a>Boutroy MJ, Gisonna CR, Legagneur M. Clonidine: placental transfer and neonatal adaption. <i>Early Hum Dev</i>. 1988;17(2-3):275-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3208682/pubmed" id="3208682" target="_blank">3208682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921528">
<a name="28921528"></a>Bruni O, Angriman M, Calisti F, et al. Practitioner review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. <i>J Child Psychol Psychiatry</i>. 2018;59(5):489-508. doi:10.1111/jcpp.12812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/28921528/pubmed" id="28921528" target="_blank">28921528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31638842">
<a name="31638842"></a>Bruni O, Angriman M, Melegari MG, Ferri R. Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders. <i>Expert Opin Pharmacother</i>. 2019;20(18):2257-2271. doi:10.1080/14656566.2019.1674283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/31638842/pubmed" id="31638842" target="_blank">31638842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19116263">
<a name="19116263"></a>Buchanan ML, Easterling TR, Carr DB, et al. Clonidine Pharmacokinetics in Pregnancy. <i>Drug Metab Dispos</i>. 2009;37(4):702-705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19116263/pubmed" id="19116263" target="_blank">19116263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8491075">
<a name="8491075"></a>Bunjes R, Schaefer C, Holzinger D. Clonidine and breast-feeding. <i>Clin Pharm</i>. 1993;12(3):178-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8491075/pubmed" id="8491075" target="_blank">8491075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3341873">
<a name="3341873"></a>Byrd BF 3rd, Collins HW, Primm RK. Risk factors for severe bradycardia during oral clonidine therapy for hypertension. <i>Arch Intern Med</i>. 1988;148(3):729-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3341873/pubmed" id="3341873" target="_blank">3341873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23728690">
<a name="23728690"></a>Cahill K, Stevens S, Perera R, Lancaste T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. <i>Cochrane Database Syst Rev.</i> 2013;(5):CD009329. doi:10.1002/14651858.CD009329.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23728690/pubmed" id="23728690" target="_blank">23728690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9649979">
<a name="9649979"></a>Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. <i>Drug Alcohol Depend</i>. 1998;50(3):251-254. doi:10.1016/s0376-8716(98)00040-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/9649979/pubmed" id="9649979" target="_blank">9649979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CatapresTTS.1">
<a name="CatapresTTS.1"></a>Catapres-TTS (clonidine) transdermal system [prescribing information]. Vacaville, CA: Alza Corporation; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35659958">
<a name="35659958"></a>Cavens L, Roofthooft E. Neuraxial labor analgesia: is there a place for neuraxial adjuvants beyond opioids. <i>Best Pract Res Clin Anaesthesiol</i>. 2022;36(1):31-36. doi:10.1016/j.bpa.2022.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/35659958/pubmed" id="35659958" target="_blank">35659958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chafin.1">
<a name="Chafin.1"></a>Chafin CC, Hovinga CA, Phelps SJ. Clonidine in the Treatment of Attention Deficit Hyperactivity Disorder. <i>Journal of Pediatric Pharmacy Practice</i>. 1999;4(6):308-315.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. <i>JAMA</i>. 2003;289(19):2560-2572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20570945">
<a name="20570945"></a>Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. <i>Drug Metab Dispos</i>. 2010;38(9):1393-1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/20570945/pubmed" id="20570945" target="_blank">20570945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clonidine.1">
<a name="Clonidine.1"></a>Clonidine [product monograph]. Mississauga, Ontario, Canada: Mint Pharmaceuticals; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clonidine.2">
<a name="Clonidine.2"></a>Clonidine Hydrochloride [prescribing information]. East Brunswick, NJ: Unichem Pharmaceuticals (USA) Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7600788">
<a name="7600788"></a>Corazza M, Mantovani L, Virgili A, Strumia R. Allergic contact dermatitis from a clonidine transdermal delivery system. <i>Contact Dermatitis</i>. 1995;32(4):246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7600788/pubmed" id="7600788" target="_blank">7600788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23838758">
<a name="23838758"></a>Cramton RE, Gruchala NE. Babies breaking bad: neonatal and iatrogenic withdrawal syndromes. <i>Curr Opin Pediatr</i>. 2013;25(4):532-542. doi:10.1097/MOP.0b013e328362cd0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23838758/pubmed" id="23838758" target="_blank">23838758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7986518">
<a name="7986518"></a>Cunningham FE, Baughman VL, Peters J, et al. Comparative Pharmacokinetics of Oral Versus Sublingual Clonidine. <i>J Clin Anesth</i>. 1994;6(5):430-433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7986518/pubmed" id="7986518" target="_blank">7986518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24679061">
<a name="24679061"></a>Devereaux PJ, Sessler DI, Leslie K, et al; POISE-2 Investigators. Clonidine in patients undergoing noncardiac surgery. <i>N Engl J Med</i>. 2014;370(16):1504-1513. doi:10.1056/NEJMoa1401106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24679061/pubmed" id="24679061" target="_blank">24679061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12725011">
<a name="12725011"></a>Donnelly CL. Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. <i>Child Adolesc Psychiatr Clin N Am</i>. 2003;12(2):251-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/12725011/pubmed" id="12725011" target="_blank">12725011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33005940">
<a name="33005940"></a>Downs JW, Cumpston KL. "Road rash" and dizziness: a case of hemodynamically significant topical clonidine toxicity. <i>Mil Med</i>. Published online October 2,2020. doi:10.1093/milmed/usaa284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/33005940/pubmed" id="33005940" target="_blank">33005940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18696285">
<a name="18696285"></a>Du YS, Li HF, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. <i>Aust N Z J Psychiatry</i>. 2008;42(9):807-813. doi:10.1080/00048670802277222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18696285/pubmed" id="18696285" target="_blank">18696285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Duraclon.1">
<a name="Duraclon.1"></a>Duraclon (clonidine hydrochloride injection) [prescribing information]. Morgantown, WV: Mylan Institutional LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33223070">
<a name="33223070"></a>Ekambaram V, Owens J. Medications used for pediatric insomnia. <i>Child Adolesc Psychiatr Clin N Am</i>. 2021;30(1):85-99. doi:10.1016/j.chc.2020.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/33223070/pubmed" id="33223070" target="_blank">33223070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.2019">
<a name="Elliott.2019"></a>Elliott WJ. Withdrawal syndromes with antihypertensive drug therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fiore.1">
<a name="Fiore.1"></a>Fiore MC, Jaen CR, Baker TB, et al. <i>Treating Tobacco Use and Dependence: 2008 Update.</i> Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. May 2008. <a href="https://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf" target="_blank">http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8659804">
<a name="8659804"></a>Fitzgibbon D, Rapp S, Butler S, et al. Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine. <i>Anesthesiology</i>. 1996;84(3):729-731. doi:10.1097/00000542-199603000-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8659804/pubmed" id="8659804" target="_blank">8659804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber D, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18839219">
<a name="18839219"></a>Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. <i>Pediatr Nephrol</i>. 2009;24(6):1101-1112. doi:10.1007/s00467-008-1000-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18839219/pubmed" id="18839219" target="_blank">18839219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7332729">
<a name="7332729"></a>Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man—evidence for dose dependency and changed pharmacokinetics during chronic therapy. <i>Br J Clin Pharmacol</i>. 1981;12(5):653-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7332729/pubmed" id="7332729" target="_blank">7332729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11886028">
<a name="11886028"></a>Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. <i>J Am Acad Child Adolesc Psychiatry.</i> 2002;41(3):330-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11886028/pubmed" id="11886028" target="_blank">11886028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28833346">
<a name="28833346"></a>Gagnon DJ, Fontaine GV, Riker RR, Fraser GL. Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: a literature review with practical considerations. <i>Pharmacotherapy</i>. 2017;37(10):1309-1321. doi:10.1002/phar.2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/28833346/pubmed" id="28833346" target="_blank">28833346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25809176">
<a name="25809176"></a>Gagnon DJ, Riker RR, Glisic EK, Kelner A, Perrey HM, Fraser GL. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. <i>Pharmacotherapy</i>. 2015;35(3):251-259. doi:10.1002/phar.1559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25809176/pubmed" id="25809176" target="_blank">25809176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10835999">
<a name="10835999"></a>Galloway KS, Yaster M. Pain and Symptom Control in Terminally Ill Children. <i>Pediatr Clin North Am</i>. 2000;47(3):711-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/10835999/pubmed" id="10835999" target="_blank">10835999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-760743">
<a name="760743"></a>Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. <i>Br J Clin Pharmacol</i>. 1979;7(1):55-62. doi:10.1111/j.1365-2125.1979.tb00897.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/760743/pubmed" id="760743" target="_blank">760743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. Published online November 15, 2013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27140827">
<a name="27140827"></a>Gowing L, Farrell M, Ali R, White JM. Alpha₂-adrenergic agonists for the management of opioid withdrawal. <i>Cochrane Database Syst Rev</i>. 2016:3;(5):CD002024. doi:10.1002/14651858.CD002024.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/27140827/pubmed" id="27140827" target="_blank">27140827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1552044">
<a name="1552044"></a>Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. <i>J Clin Psychopharmacol</i>. 1992;12(1):69-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/1552044/pubmed" id="1552044" target="_blank">1552044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3822302">
<a name="3822302"></a>Hartikainen-Sorri AL, Heikkinen JE, Koivisto M. Pharmacokinetics of clonidine during pregnancy and nursing. <i>Obstet Gynecol</i>. 1987;69(4):598-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3822302/pubmed" id="3822302" target="_blank">3822302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433274">
<a name="19433274"></a>Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. <i>Pediatr Neurol</i>. 2009;40(6):420-425. doi:10.1016/j.pediatrneurol.2008.12.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19433274/pubmed" id="19433274" target="_blank">19433274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6597462">
<a name="6597462"></a>Hoder EL, Leckman JF, Poulsen J, et al. Clonidine treatment of neonatal narcotic abstinence syndrome. <i>Psychiatry Res</i>. 1984;13(3):243-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/6597462/pubmed" id="6597462" target="_blank">6597462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6115570">
<a name="6115570"></a>Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. <i>Am Heart J.</i> 1981;102(3, pt 1):415-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/6115570/pubmed" id="6115570" target="_blank">6115570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29486974">
<a name="29486974"></a>Hoyt MR, Shah U, Cooley J, Temple M. Use of epidural clonidine for the management of analgesia in the opioid addicted parturient on buprenorphine maintenance therapy: an observational study. <i>Int J Obstet Anesth</i>. 2018;34:67-72. doi:10.1016/j.ijoa.2018.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/29486974/pubmed" id="29486974" target="_blank">29486974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487765">
<a name="11487765"></a>Huang C, Banerjee K, Sochett E, et al. Hypoglycemia Associated With Clonidine Testing for Growth Hormone Deficiency. <i>J Pediatr</i>. 2001;139(2):323-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11487765/pubmed" id="11487765" target="_blank">11487765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC. Neonatal Drug Withdrawal. <i>Pediatrics</i>. 2012;129(2):e540-e560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3602304">
<a name="3602304"></a>Hunt RD. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. <i>Psychopharmacol Bull</i>. 1987;23(1):111-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3602304/pubmed" id="3602304" target="_blank">3602304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hunt.1">
<a name="Hunt.1"></a>Hunt RD, Capper L, O'Connell P. Clonidine in Child and Adolescent Psychiatry. <i>J Child Adol Psychpharm</i>. 1990;1(1):87-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3523578">
<a name="3523578"></a>Hunt RD, Minderaa RB, Cohen DJ. The Therapeutic Effect of Clonidine in Attention Deficit Disorder With Hyperactivity: A Comparison With Placebo and Methylphenidate. <i>Psychopharmacol Bull</i>. 1986;22(1):229-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3523578/pubmed" id="3523578" target="_blank">3523578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2916871">
<a name="2916871"></a>Jaker M, Atkin S, Soto M, et al. Oral Nifedipine vs Oral Clonidine in the Treatment of Urgent Hypertension. <i>Arch Intern Med</i>. 1989;149(2):260-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/2916871/pubmed" id="2916871" target="_blank">2916871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kapvay.1">
<a name="Kapvay.1"></a>Kapvay (clonidine) [prescribing information]. Dublin 9, Ireland: Concordia Pharmaceuticals; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15857353">
<a name="15857353"></a>Karachalios GN, Charalabopoulos A, Papalimneou V, et al. Withdrawal syndrome following cessation of antihypertensive drug therapy. <i>Int J Clin Pract</i>. 2005;59(5):562-570. doi:10.1111/j.1368-5031.2005.00520.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15857353/pubmed" id="15857353" target="_blank">15857353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15806502">
<a name="15806502"></a>K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. <i>Am J Kidney Dis.</i> 2005;45(4)(suppl 3):S1-S153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15806502/pubmed" id="15806502" target="_blank">15806502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8496122">
<a name="8496122"></a>Kemph JP, DeVane CL, Levin GM, Jarecke R, Miller RL. Treatment of aggressive children with clonidine: results of an open pilot study. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(3):577-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/8496122/pubmed" id="8496122" target="_blank">8496122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kleber.1">
<a name="Kleber.1"></a>Kleber HD, Weiss RD, Anton RF Jr, et al; Work Group on Substance Use Disorders. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders. 2nd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf. Published August 2006. Accessed March 31, 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070299">
<a name="25070299"></a>Kocherlakota P. Neonatal abstinence syndrome. <i>Pediatrics</i>. 2014;134(2):e547-e561. doi:10.1542/peds.2013-3524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25070299/pubmed" id="25070299" target="_blank">25070299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29643617">
<a name="29643617"></a>Kumari I, Sharma K, Bedi V, Mohan M, Tungaria H, Modi MK. Comparison of ropivacaine (0.2%) with or without clonidine 1 μg/kg for epidural labor analgesia: a randomized controlled study. <i>J Anaesthesiol Clin Pharmacol</i>. 2018;34(1):18-22. doi:10.4103/joacp.JOACP_233_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/29643617/pubmed" id="29643617" target="_blank">29643617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040621">
<a name="7040621"></a>Lanes R, Hurtado E. Oral Clonidine - an Effective Growth Hormone-releasing Agent in Prepubertal Subjects. <i>J Pediatric</i>. 1982;100(5):710-714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7040621/pubmed" id="7040621" target="_blank">7040621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2009034">
<a name="2009034"></a>Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine treatment of Gilles de la Tourette's syndrome. <i>Arch Gen Psychiatry</i>. 1991;48(4):324-328. doi:10.1001/archpsyc.1991.01810280040006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/2009034/pubmed" id="2009034" target="_blank">2009034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9262751">
<a name="9262751"></a>Lee HA, Anderson PO. Giving Partial Doses of Transdermal Patches. <i>Am J Health Syst Pharm</i>. 1997;54(15):1759-1760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/9262751/pubmed" id="9262751" target="_blank">9262751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26370679">
<a name="26370679"></a>Lee HM, Ruggoo V, Graudins A. Intrathecal clonidine pump failure causing acute withdrawal syndrome with 'stress-induced' cardiomyopathy. <i>J Med Toxicol</i>. 2016;12(1):134-138. doi:10.1007/s13181-015-0505-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26370679/pubmed" id="26370679" target="_blank">26370679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19566381">
<a name="19566381"></a>Leikin JB, Mackendrick WP, Maloney GE, et al. Use of Clonidine in the Prevention and Management of Neonatal Abstinence Syndrome. <i>Clin Toxicol (Phila)</i>. 2009;47(6):551-555.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/19566381/pubmed" id="19566381" target="_blank">19566381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363412">
<a name="9363412"></a>Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. <i>Drug Alcohol Depend</i>. 1997;48(2):127-133. doi:10.1016/s0376-8716(97)00116-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/9363412/pubmed" id="9363412" target="_blank">9363412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lonnqvist.1">
<a name="Lonnqvist.1"></a>Lonnqvist PA, Bergendahl H. Pharmacokinetics and haemodynamic response after an intravenous bolus injection of clonidine in children. <i>Paediatric Anaesthesia</i>. 1993;3:359-364.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3293868">
<a name="3293868"></a>Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. <i>Clin Pharmacokinet.</i> 1988;14(5):287-310. doi:10.2165/00003088-198814050-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3293868/pubmed" id="3293868" target="_blank">3293868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4028622">
<a name="4028622"></a>MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of Transdermally Delivered Clonidine. <i>Clin Pharmacol Ther</i>. 1985;38(3):278-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/4028622/pubmed" id="4028622" target="_blank">4028622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MarClonidine.1">
<a name="MarClonidine.1"></a>Mar-Clonidine (clonidine hydrochloride) [product monograph]. Ottawa, Ontario, Canada: Marcan Pharmaceuticals Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29219631">
<a name="29219631"></a>Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. <i>Expert Rev Neurother</i>. 2018;18(2):125-137. doi:10.1080/14737175.2018.1413938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/29219631/pubmed" id="29219631" target="_blank">29219631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Matuschka.1">
<a name="Matuschka.1"></a>Matuschka PR. Safer Alternatives to Sublingual Nifedipine for the Treatment of Hypertensive Urgencies. <i>J Pharm Technol</i>. 1999;15:199-203.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30697133">
<a name="30697133"></a>Meddock RP, Bloemer D. Evaluation of the cardiovascular effects of clonidine in neonates treated for neonatal abstinence syndrome. <i>J Pediatr Pharmacol Ther</i>. 2018;23(6):473-478. doi:10.5863/1551-6776-23.6.473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/30697133/pubmed" id="30697133" target="_blank">30697133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3026180">
<a name="3026180"></a>Metz S, Klein C, Morton N. Rebound hypertension after discontinuation of transdermal clonidine therapy. <i>Am J Med</i>. 1987;82(1):17-19. doi:10.1016/0002-9343(87)90371-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/3026180/pubmed" id="3026180" target="_blank">3026180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16740821">
<a name="16740821"></a>Mindell JA, Emslie G, Blumer J, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. <i>Pediatrics</i>. 2006;117(6):e1223-e1232. doi:10.1542/peds.2005-1693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/16740821/pubmed" id="16740821" target="_blank">16740821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Muluk.2019">
<a name="Muluk.2019"></a>Muluk V, Cohn SL, Whinney C. Perioperative medication management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE clinical guideline NG87. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87/chapter/recommendations. Published March 14, 2018. Accessed August 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Care Excellence (NICE). NICE guideline hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9884677">
<a name="9884677"></a>Newcorn JH, Schulz K, Harrison M, DeBellis MD, Udarbe JK, Halperin JM. Alpha 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. <i>Pediatr Clin North Am</i>. 1998;45(5):1099-viii. doi:10.1016/s0031-3955(05)70064-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/9884677/pubmed" id="9884677" target="_blank">9884677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NexiclonXR.1">
<a name="NexiclonXR.1"></a>Nexiclon XR (clonidine) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>NHBPEP (National High Blood Pressure Education Program) Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl 4th Report):555-576. <a href="http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf" target="_blank">http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5568234">
<a name="5568234"></a>Onesti G, Schwartz AB, Kim KE, Paz-Martinez V, Swartz C. Antihypertensive effect of clonidine. <i>Circ Res</i>. 1971;28(5)(suppl 2):53-69. doi:10.1161/01.res.28.5.ii-53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/5568234/pubmed" id="5568234" target="_blank">5568234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33245274">
<a name="33245274"></a>Ornoy A, Koren G. The effects of drugs used for the treatment of attention deficit hyperactivity disorder (ADHD) on pregnancy outcome and breast-feeding: a critical review. <i>Curr Neuropharmacol</i>. 2021;19(11):1794-1804. doi:10.2174/1570159X18666201127164000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/33245274/pubmed" id="33245274" target="_blank">33245274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21984028">
<a name="21984028"></a>Pandazi A, Karamanis P, Sidiropoulou T, et al. Low-dose (1 microg/kg) clonidine premedication and hypotension after carotid artery surgery. <i>Vasc Endovascular Surg</i>. 2011;45(7):614-618. doi:10.1177/1538574411414300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/21984028/pubmed" id="21984028" target="_blank">21984028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12656438">
<a name="12656438"></a>Porter DM, Bell CC. The use of clonidine in post-traumatic stress disorder. <i>J Natl Med Assoc</i>. 1999;91(8):475-477.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/12656438/pubmed" id="12656438" target="_blank">12656438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15983000">
<a name="15983000"></a>Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea? <i>J Psychopharmacol</i>. 2005;19(4):426-428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/15983000/pubmed" id="15983000" target="_blank">15983000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397999">
<a name="22397999"></a>Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/22397999/pubmed" id="22397999" target="_blank">22397999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31865218">
<a name="31865218"></a>Richmond E, Rogol AD. Testing for growth hormone deficiency in children. <i>Growth Horm IGF Res</i>. 2020;50:57-60. doi:10.1016/j.ghir.2019.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/31865218/pubmed" id="31865218" target="_blank">31865218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18425584">
<a name="18425584"></a>Richmond EJ, Rogol AD. Growth Hormone Deficiency in Children. <i>Pituitary</i>. 2008;11(2):115-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18425584/pubmed" id="18425584" target="_blank">18425584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association; American College of Cardiology; American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santen.2020">
<a name="Santen.2020"></a>Santen RJ, Loprinzi CL, Casper RF. Menopausal hot flashes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sevarino.1">
<a name="Sevarino.1"></a>Sevarino K. Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24411570">
<a name="24411570"></a>Sevrez C, Lavocat MP, Mounier G, et al. Transplacental or breast milk intoxication to clonidine: a case of neonatal hypotonia and drowsiness. <i>Arch Pediatr</i>. 2014;21(2):198-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24411570/pubmed" id="24411570" target="_blank">24411570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16227779">
<a name="16227779"></a>Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. <i>J Clin Hypertens (Greenwich)</i>. 2005;7(9):558-562. doi:10.1111/j.1524-6175.2005.04133.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/16227779/pubmed" id="16227779" target="_blank">16227779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23757186">
<a name="23757186"></a>Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. <i>CNS Drugs</i>. 2013;27(7):531-543. doi:10.1007/s40263-013-0084-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23757186/pubmed" id="23757186" target="_blank">23757186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stolbach.2019">
<a name="Stolbach.2019"></a>Stolbach A, Hoffman RS. Opioid withdrawal in the emergency setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20441729">
<a name="20441729"></a>Strawn JR, Keeshin BR, DelBello MP, Geracioti TD Jr, Putnam FW. Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents: a review. <i>J Clin Psychiatry</i>. 2010;71(7):932-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/20441729/pubmed" id="20441729" target="_blank">20441729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27092265">
<a name="27092265"></a>Terry K, Blum R, Szumita P. Evaluating the transition from dexmedetomidine to clonidine for agitation management in the intensive care unit.<i> SAGE Open Med.</i> Published online December 15, 2015. doi:10.1177/2050312115621767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/27092265/pubmed" id="27092265" target="_blank">27092265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7949510">
<a name="7949510"></a>Tom GR, Premer M. Hydrocortisone Cream in Clonidine Patch Dermatitis. <i>Ann Pharmacother.</i> 1994;28(7-8):889-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/7949510/pubmed" id="7949510" target="_blank">7949510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11865128">
<a name="11865128"></a>Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. <i>Neurology.</i> 2002;58(4):527-536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/11865128/pubmed" id="11865128" target="_blank">11865128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2015">
<a name="VADoD.2015"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varon.1">
<a name="Varon.1"></a>Varon J, Elliott WJ. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896146">
<a name="21896146"></a>Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central sympatholytic drugs. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(9):658-661. doi:10.1111/j.1751-7176.2011.00509.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/21896146/pubmed" id="21896146" target="_blank">21896146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23099282">
<a name="23099282"></a>Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/23099282/pubmed" id="23099282" target="_blank">23099282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003063">
<a name="22003063"></a>Wolraich M, Brown L, Brown RT, et al: Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2011;128(5):1007-1022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/22003063/pubmed" id="22003063" target="_blank">22003063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31570648">
<a name="31570648"></a>Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2019;144(4):e20192528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/31570648/pubmed" id="31570648" target="_blank">31570648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36377919">
<a name="36377919"></a>Xia F, Wang LZ, Chang XY, Zhang YF. Efficacy and safety of epidural clonidine by continuous infusion or patient-controlled analgesia in labor: a meta-analysis of randomized controlled trials. <i>Int J Gynaecol Obstet</i>. 2022. doi:10.1002/ijgo.14579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/36377919/pubmed" id="36377919" target="_blank">36377919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20484620">
<a name="20484620"></a>Xie HG, Cao YJ, Gauda EB, Agthe AG, Hendrix CW, Lee H. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. <i>J Clin Pharmacol</i>. 2011;51(4):502-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/20484620/pubmed" id="20484620" target="_blank">20484620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25369869">
<a name="25369869"></a>Zhang N, Xu MJ. Effects of epidural neostigmine and clonidine in labor analgesia: a systematic review and meta-analysis. <i>J Obstet Gynaecol Res</i>. 2015;41(2):214-221. doi:10.1111/jog.12517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clonidine-drug-information/abstract-text/25369869/pubmed" id="25369869" target="_blank">25369869</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9285 Version 726.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
